Completed NA INTERVENTIONAL 1-arm NCT00100568

Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in Senegal

A Pilot Study of Safety, Effectiveness, and Adherence of Lamivudine/Zidovudine and Efavirenz (3TC/ZDV + EFV) to Treat HIV-1 Infection in Senegal

Sponsor: Initiative Senegalaise d'Acces aux Antiretroviraux (ISAARV)

Conditions HIV Infections

Interventions Efavirenz Lamivudine/zidovudine

Updated 6 times since 2017 Last updated: Sep 4, 2013 Started: Jul 31, 2006 Primary completion: Jun 30, 2009 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00100568, this NA trial focuses on HIV Infections and remains completed. Sponsored by Initiative Senegalaise d'Acces aux Antiretroviraux (ISAARV), it has been updated 6 times since 2006, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Feb 2017 — Jun 2018 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Initiative Senegalaise d'Acces aux Antiretroviraux (ISAARV)
National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dakar, Senegal